Table 3. Main clinical trials in research on the new molecular targets of ICIs in NSCLC.

Trial	Phase	Drug	Trial design	Stage and indication
NCT03625323	2	LAG-3: IMP321 (eftilagimod alpha)	Pembrolizumab + IMP321	Untreated metastatic NSCLC
NCT04623775	2	LAG-3: BMS-986016 (relatlimab)	Relatlimab + nivolumab + CT vs. nivolumab + CT	First line metastatic NSCLC
NCT04140500	1	LAG-3: RO7247669	Dose escalation study of bispecific antibody PD-1-LAG-3	Metastatic NSCLC
NCT03322540	2	IDO1: INCB024360 (epacadostat)	Epacadostat + pembrolizumab vs. pembrolizumab	First line metastatic NSCLC and high levels of PD-L1
NCT04294810	3	TIGIT: MTIG7192A (tiragolumab)	Tiragolumab + atezolizumab vs. atezolizumab	First line metastatic NSCLC with PD-L1 ≥50%
NCT04738487	3	TIGIT: MK-7684A (vibostolimab)	Vibostolimab + pembrolizumab vs. pembrolizumab	Metastatic NSCLC with PD-L1 ≥1%
NCT03822351	2	NKG2A: IPH2201 (monalizumab)	Durvalumab vs. durvalumab + oleclumab vs. durvalumab + monalizumab	Stage III NSCLC after treatment with CT/RT
		CD73: MEDI-9447 (oleclumab)
NCT03381274	1/2	CD73: MEDI-9447 (oleclumab)	Oleclumab + osimertinib vs. MEDI9447 + AZD4635	EGFRm NSCLC
NCT03549000	1	CD73: NZV930	NZV930 vs. NZV930 + PDR001 vs. NZV930 + NIR178 vs. NZV930 + PDR001 + NIR178	Metastatic NSCLC
NCT02475213	1	B7-H3: MGA271 (enoblituzumab)	Enoblituzumab + pembrolizumab	Metastatic NSCLC
NCT02381314	1	B7-H3: MGA271 (enoblituzumab)	Enoblituzumab + ipilimumab	Metastatic NSCLC
NCT03729596	1/2	B7-H3·: MGC018	MGC018 vs. MGC018 + retifanlimab	Metastatic NSCLC
NCT04081688	1	CD27: CDX-1127 (varlimumab)	Varlimumab + atezolizumab + SBRT	Metastatic NSCLC
NCT03708328	1	TIM3: RO7121661	Dose escalation study of bispecific antibody PD-1/TIM3	Metastatic NSCLC

ICIs, immune checkpoint inhibitors; NSCLC, non-small cell lung cancer; LAG-3, lymphocyte activation gene-3; CT, chemotherapy; RT, radiotherapy.